发明名称 |
DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS |
摘要 |
The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question. |
申请公布号 |
US2015037810(A1) |
申请公布日期 |
2015.02.05 |
申请号 |
US201313954080 |
申请日期 |
2013.07.30 |
申请人 |
Blume-Jensen Peter |
发明人 |
Blume-Jensen Peter |
分类号 |
G01N33/50 |
主分类号 |
G01N33/50 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of identifying a cancer type of interest, comprising:
(a) establishing a cellular model of cancer space based on two or more cell lines each having one or more disease signaling pathways causally involved in cancer type of interest; (b) treating the two or more cell lines with one or more exogenous agents; (c) using phosphor-antibodies (P-Abs) to analyze phosphopathways of one or more biomarkers before and after treatment with the exogenous agents; (d) determining the effect of the exogenous agents on an activity state of the one or more disease signaling pathways in the cell lines by identifying at least one of: (i) abundance of one or more biomarkers, and (ii) post-translational modifications of one or more biomarkers, before and after treatment with the one or more exogenous agents through phosphopathway analysis using phosphor-antibodies (P-Abs); (e) deriving one or more biomarkers for an activity state of the one or more disease signaling pathways in the cell lines from the one or more biomarkers; and (f) defining the cancer type based on the one or more disease signaling pathways and responsiveness of the pathways to the one or more exogenous agents. |
地址 |
Westfield NJ US |